Replay CEO Lachlan MacKinnon (L) and president Adrian Woolfson
Maker of new gene therapy vector launches its second company, looking to zero in on rare skin conditions
The hub-and-spoke biotech Replay, which came onto the scene with $55 million in seed capital and a vision to launch four companies around its …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
